

REMARKS/ARGUMENTS

Reconsideration of the captioned application is respectfully requested in view of the amendments above and the following remarks.

After entry of the amendment, Claims 4 to 6, 19 and 20 will be pending in the application. Claims 4 and 5 have been amended herein, without prejudice.

Claim 4 has been amended so as to exclude unelected subject matter. It is believed this amendment overcomes the objection set forth on page 6 of the Office Action.

Claim 5, as amended herein, is directed to methods treating a disorder selected from the group consisting of depression, anxiety disorder, panic disorder, obsessive-compulsive disorder, abnormal aggression, unstable angina, reactive hypertension, anorexia nervosa, bulimia, irritable bowel syndrome, stress-induced immune suppression, stroke, inflammation, Cushing's disease, infantile spasms, epilepsy, and substance abuse or withdrawal in a warm-blooded animal. This amendment is supported in the specification, for example, at page 18, lines 4 to 10.

In the Office Action dated December 30, 2002, Claim 5 stood rejected under 35 U.S.C. § 112, first paragraph. Basically, it was asserted that original Claim 5 was not enabled, because it covered not only conditions which are known to be amenable to treatment with CRF antagonists, but also conditions yet to be discovered that may be characterized by overexpression of CRF. While Applicants respectfully disagree with the Examiner regarding this rejection, in the interest of advancing this application to allowance, Applicants have amended Claim 5 to encompass the conditions specifically set forth in the specification. In view of this amendment, Applicants respectfully request that the rejection be withdrawn.

DOCKET NO.: PH-7345-A (BMS-0891)
Application No.: 09/995,159
Office Action Dated: December 30, 2002

PATENT

There being no further issues regarding this application, Applicants respectfully request a Notice of Allowance of pending Claims 4 to 6, 19 and 20.

If there are any additional issues, or if the Examiner wishes to discuss this application further, please telephone the Applicants' undersigned representative at the number below. Applicants note, however, that all written correspondence for this application should continue to be sent to:

Bristol-Myers Squibb Company
Patent Department
PO Box 4000
Route 206 and Provinceline Road
Princeton, NJ 08453-4000.

Date: April 30, 2003



S. Maurice Valla
Registration No. 43,966

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439